185 related articles for article (PubMed ID: 33130290)
1. The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
Yogiara ; Mordukhova EA; Kim D; Kim WG; Hwang JK; Pan JG
Bioorg Med Chem Lett; 2020 Dec; 30(24):127651. PubMed ID: 33130290
[TBL] [Abstract][Full Text] [Related]
2. Ligand- and Structure-Based Approaches of Escherichia coli FabI Inhibition by Triclosan Derivatives: From Chemical Similarity to Protein Dynamics Influence.
Kronenberger T; de Oliveira Fernades P; Drumond Franco I; Poso A; Gonçalves Maltarollo V
ChemMedChem; 2019 Dec; 14(23):1995-2004. PubMed ID: 31670463
[TBL] [Abstract][Full Text] [Related]
3. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
Bergler H; Fuchsbichler S; Högenauer G; Turnowsky F
Eur J Biochem; 1996 Dec; 242(3):689-94. PubMed ID: 9022698
[TBL] [Abstract][Full Text] [Related]
4. Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.
Yao J; Zhang Q; Min J; He J; Yu Z
Bioorg Med Chem Lett; 2010 Jan; 20(1):56-9. PubMed ID: 19959361
[TBL] [Abstract][Full Text] [Related]
5. Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase.
Massengo-Tiassé RP; Cronan JE
J Biol Chem; 2008 Jan; 283(3):1308-1316. PubMed ID: 18032386
[TBL] [Abstract][Full Text] [Related]
6. FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors.
Rana P; Ghouse SM; Akunuri R; Madhavi YV; Chopra S; Nanduri S
Eur J Med Chem; 2020 Dec; 208():112757. PubMed ID: 32883635
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore and molecular docking guided 3D-QSAR study of bacterial enoyl-ACP reductase (FabI) Inhibitors.
Lu X; Lv M; Huang K; Ding K; You Q
Int J Mol Sci; 2012; 13(6):6620-6638. PubMed ID: 22837653
[TBL] [Abstract][Full Text] [Related]
8. Escherichia coli enoyl-acyl carrier protein reductase (FabI) supports efficient operation of a functional reversal of β-oxidation cycle.
Vick JE; Clomburg JM; Blankschien MD; Chou A; Kim S; Gonzalez R
Appl Environ Microbiol; 2015 Feb; 81(4):1406-16. PubMed ID: 25527535
[TBL] [Abstract][Full Text] [Related]
9. Role of inhibitor aliphatic chain in the thermodynamics of inhibitor binding to Escherichia coli enoyl-ACP reductase and the Phe203Leu mutant: a proposed mechanism for drug resistance.
Protasevich II; Brouillette CG; Snow ME; Dunham S; Rubin JR; Gogliotti R; Siegel K
Biochemistry; 2004 Oct; 43(42):13380-9. PubMed ID: 15491144
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs.
Sivaraman S; Zwahlen J; Bell AF; Hedstrom L; Tonge PJ
Biochemistry; 2003 Apr; 42(15):4406-13. PubMed ID: 12693936
[TBL] [Abstract][Full Text] [Related]
11. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli.
Heath RJ; Rock CO
J Biol Chem; 1995 Nov; 270(44):26538-42. PubMed ID: 7592873
[TBL] [Abstract][Full Text] [Related]
12. ucFabV Requires Functional Reductase Activity to Confer Reduced Triclosan Susceptibility in Escherichia coli.
Fischer TL; White RJ; Mares KF; Molnau DE; Donato JJ
J Mol Microbiol Biotechnol; 2015; 25(6):394-402. PubMed ID: 26683704
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.
Seefeld MA; Miller WH; Newlander KA; Burgess WJ; Payne DJ; Rittenhouse SF; Moore TD; DeWolf WE; Keller PM; Qiu X; Janson CA; Vaidya K; Fosberry AP; Smyth MG; Jaworski DD; Slater-Radosti C; Huffman WF
Bioorg Med Chem Lett; 2001 Sep; 11(17):2241-4. PubMed ID: 11527706
[TBL] [Abstract][Full Text] [Related]
14. Signature gene expression profile of triclosan-resistant Escherichia coli.
Yu BJ; Kim JA; Pan JG
J Antimicrob Chemother; 2010 Jun; 65(6):1171-7. PubMed ID: 20410062
[TBL] [Abstract][Full Text] [Related]
15. 2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI.
Ramnauth J; Surman MD; Sampson PB; Forrest B; Wilson J; Freeman E; Manning DD; Martin F; Toro A; Domagala M; Awrey DE; Bardouniotis E; Kaplan N; Berman J; Pauls HW
Bioorg Med Chem Lett; 2009 Sep; 19(18):5359-62. PubMed ID: 19682900
[TBL] [Abstract][Full Text] [Related]
16. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).
Heerding DA; Chan G; DeWolf WE; Fosberry AP; Janson CA; Jaworski DD; McManus E; Miller WH; Moore TD; Payne DJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Smith W; Takata DT; Vaidya KS; Yuan CC; Huffman WF
Bioorg Med Chem Lett; 2001 Aug; 11(16):2061-5. PubMed ID: 11514139
[TBL] [Abstract][Full Text] [Related]
17. Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI).
Sampson PB; Picard C; Handerson S; McGrath TE; Domagala M; Leeson A; Romanov V; Awrey DE; Thambipillai D; Bardouniotis E; Kaplan N; Berman JM; Pauls HW
Bioorg Med Chem Lett; 2009 Sep; 19(18):5355-8. PubMed ID: 19682901
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): a target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis.
Hoang TT; Schweizer HP
J Bacteriol; 1999 Sep; 181(17):5489-97. PubMed ID: 10464225
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.
Takahata S; Iida M; Yoshida T; Kumura K; Kitagawa H; Hoshiko S
J Antibiot (Tokyo); 2007 Feb; 60(2):123-8. PubMed ID: 17420562
[TBL] [Abstract][Full Text] [Related]
20. Reduced Susceptibility to Antiseptics Is Conferred by Heterologous Housekeeping Genes.
Tansirichaiya S; Reynolds LJ; Cristarella G; Wong LC; Rosendahl K; Roberts AP
Microb Drug Resist; 2018 Mar; 24(2):105-112. PubMed ID: 28604259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
